Sionna Therapeutics (NASDAQ:SION) Releases Earnings Results, Misses Expectations By $0.10 EPS

Sionna Therapeutics (NASDAQ:SION) posted its quarterly earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.10), FiscalAI reports.

Here are the key takeaways from Sionna Therapeutics’ conference call:

• The Phase IIa PreciSION study missed the company’s efficacy expectations, disappointing management. A post hoc analysis excluding three patients it considered non-adherent showed a 4-to-9-point sweat-chloride improvement, still below its 10-point target.
• Sionna hypothesizes that combining SION-719 with TRIKAFTA caused “anti-synergy,” including a 25%–30% drop in TRIKAFTA exposure and a possible biological interaction with its potentiator. The company said the small dataset and sparse pharmacokinetic measurements prevent it from confirming or quantifying these explanations.
• Sionna plans to start a Phase II proof-of-concept study in the first quarter, testing a 28-day, open-label switch from TRIKAFTA to its potentiator-free SION-451/SION-2222 combination, with sweat chloride as the primary activity endpoint. The protocol and study size are still being finalized, so the efficacy and enrollment outlook remain uncertain.
• The company reported $250 million in cash at the end of Q3 and runway into the second half of 2029, providing funding for its planned clinical work.

Sionna Therapeutics Stock Up 2.8%

NASDAQ SION traded up $0.10 on Wednesday, reaching $3.81. The company had a trading volume of 37,237 shares, compared to its average volume of 968,495. The stock has a market capitalization of $172.03 million, a PE ratio of -1.75 and a beta of 1.23. The firm’s 50 day moving average price is $5.12 and its 200 day moving average price is $28.83. Sionna Therapeutics has a 12 month low of $3.19 and a 12 month high of $54.97.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on SION. Wall Street Zen downgraded Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. JonesTrading lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Stifel Nicolaus cut shares of Sionna Therapeutics from a “buy” rating to a “hold” rating and set a $7.00 target price on the stock. in a research note on Monday, August 10th. Lifesci Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 10th. Finally, Wedbush lifted their price target on shares of Sionna Therapeutics from $5.00 to $6.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $42.33.

Insider Transactions at Sionna Therapeutics

In other Sionna Therapeutics news, Director Ra Capital Management, L.P. sold 3,448,811 shares of Sionna Therapeutics stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $6.33, for a total value of $21,830,973.63. Following the sale, the director owned 3,448,812 shares of the company’s stock, valued at $21,830,979.96. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Alps Advisors Inc. boosted its position in Sionna Therapeutics by 30.6% during the 3rd quarter. Alps Advisors Inc. now owns 59,475 shares of the company’s stock valued at $313,000 after acquiring an additional 13,950 shares in the last quarter. Chicago Partners Investment Group LLC purchased a new stake in shares of Sionna Therapeutics during the 3rd quarter worth $39,000. State of Alaska Department of Revenue purchased a new stake in shares of Sionna Therapeutics during the 3rd quarter worth $105,000. Engineers Gate Manager LP bought a new stake in Sionna Therapeutics during the second quarter valued at about $686,000. Finally, AXQ Capital LP bought a new stake in Sionna Therapeutics during the second quarter valued at about $202,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. The company is working to address the underlying cause of CF by developing small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s research centers on the nucleotide-binding domain 1 (NBD1) of CFTR, which plays an important role in the protein’s structure and activity.